A new Report by Delvens, titled "Non-opioid Pain Treatment Market” offers a comprehensive analysis of the industry, which comprises insights on the Global analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market.
The global Non-opioid Pain Treatment Market size is projected to reach a CAGR of 7.1% from 2023-2030.
Get Free Sample Report: https://www.delvens.com/get-free-sample/non-opiod-pain-treatment-market
The growing incidence of chronic pain is due to the prevalence of server pain-causing conditions such as arthritis, cancer pain, and neuropathic pain. This created a demand for effective pain management solutions, where consumers looking for non-invasive and non-pharmacological methods to treat these kinds of pain that open up opportunities for non-opioid pain treatments. Further, the consumers are aware of the side effects and risks associated with opioid-based treatment which drives them to make use of non-opioid-based pain interventions. Moreover, the enhancement in alternative treatments such as nerve blockers, cannabinoids, alternative therapies like acupuncture and physical therapy, and government awareness programs on reducing opioid drug abuse continues to grow the market of non-opioid pain treatment in the next coming years.
Competitive Landscape
· Novartis AG
· Teva Pharmaceutical Industries Limited
· Dr. Reddy’s Laboratories Ltd
· Sun Pharmaceutical Industries Ltd
· GSK plc.
· Pfizer Inc.
· Perrigo Company plc
· LNK International, Inc.
· Cipla Inc.
· Johnson & Johnson Services, Inc.
· Pacira Pharmaceuticals, Inc.
· Pierrel
· Eli Lilly and company (U.S.)
· Regeneron Pharmaceuticals Inc.
Recent Developments
· In January 2021, a Duke-led team of scientists developed a biocompatible surgical patch that delivers non-opioid medicines to the wound site for days before dissolving. The novel polymer patch administers a regulated release of a medication that blocks the enzyme COX-2 (cyclooxygenase-2,) which is responsible for inflammation and pain.
· In May 2022, Hisamitsu America Celebrates Salonpas Day with Free Patch Offer from Doctor Recommended OTC Pain Relief Patch Brand. Salonpas was named the number-one doctor-recommended brand of pain relief patches in the United States in 2021
· In February 2022, NEXGEL, Inc., a provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, reported the launch of its MEDAGEL Bug Bite Relief Patch. These cooling patches, made in the USA using NEXGEL's soothing hydrogel technology, provide instant relief to irritated skin caused by insect bites.
For More Inquiry Contact us: https://www.delvens.com/Inquire-before-buying/non-opiod-pain-treatment-market
Regional Analysis
North America to Dominate the Market
· North America dominated the non-opioid pain treatment industry and accounted for the largest revenue share.
· This dominance can be attributed to the high demand for NSAIDs, proactive government measures for limiting opioid use, improvements in healthcare infrastructure, and the presence of major players. Favourable government initiatives and reimbursement policies are likely to drive market growth.
Key Findings
· The drug class segment is further fragmented into NSAIDs, Acetaminophen, Local Anaesthetics and Others. The nonsteroidal anti-inflammatory drugs (NSAIDs) segment dominated the industry and accounted for the largest revenue share. The growth of the segment is due to the wide availability of effective NSAID medications with low costs and safer alternatives to opioids for treatment.
· The pain type segment is further fragmented into Chronic Pain, Post-operative Pain, Cancer Pain and Others. The chronic pain segment dominated the market with the largest revenue share.
· The route of administration segment is further fragmented into Oral, Injectable, Topical and Others. The oral segment dominated the non-opioid analgesics market and accounted for the largest revenue share. The growth of the segment is due to the approval and launch of new oral NSAIDs for pain management. Key oral non-opioid analgesics drug prescribed by physicians to their patients for pain management includes Celebrex (celecoxib), Cambia, Cataflam, Dyloject, Zipsor, and Zorvolex (diclofenac potassium), Anaprox, Anaprox Ds, Ec-Naprosyn, Naprosyn, Naprelan, and Treximet (naproxen sodium), Lodine (etodolac), Nalfon (fenoprofen), Motrin & Advil (ibuprofen), and Daypro (oxaprozin), among others.
· The distribution channel segment is further fragmented into Hospital Pharmacy, Retail Pharmacy and Others. The retail pharmacy segment dominated the non-opioid pain treatment market and accounted for the largest revenue share. The growth is majorly due to the wide availability of non-opioid analgesic drugs and easy accessibility to medicines for patients.
The Report helps to identify the opportunities in Global Regions:
· North America (the United States, Canada, and Mexico)
· Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
· Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))
· South America (Brazil etc.)
· The Middle East and Africa (North Africa and GCC Countries)
Access Full Report: https://www.delvens.com/report/non-opiod-pain-treatment-market
In addition to the market data for Non-opioid Pain Treatment Market, Delvens offers client-centric report and customized according to the company’s specific demand and requirement.
Reasons to Acquire
· Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors.
· Gain authentic and granular data access for Non-opioid Pain Treatment Market so as to understand the trends and the factors involved behind changing market situations.
· Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
· In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.
Frequently Asked Questions
· What are the years considered to study Non-opioid Pain Treatment Market intelligence report?
· What is the compound annual growth rate (CAGR) of the Non-opioid Pain Treatment Market?
· Which region holds the largest market share in Non-opioid Pain Treatment Market?
· Which region holds the largest market share in Non-opioid Pain Treatment Market?
· Who are the major players in Non-opioid Pain Treatment Market?
More Reports from Delvens:
Clinical Analysis Market size was estimated at USD 61.3 billion in 2023 and is projected to reach USD 98.43 billion in 2030 at a CAGR of 7% during the forecast period 2024-2030.
Microbiology Analysis Market size was estimated at USD 5.45 billion in 2023 and is projected to reach USD 10.07 billion in 2030 at a CAGR of 9.15% during the forecast period 2024-2030.
About Us:
Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.
Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.
Contact us:
UNIT NO. 2126, TOWER B,
21ST FLOOR ALPHATHUM
SECTOR 90 NOIDA 201305, IN
+44-20-3290-6466
+1 214-377-1144
